{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:05:27Z","timestamp":1790345127097,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartfailure.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.hfc.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T16:01:44Z","timestamp":1447257704000},"page":"31-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Acute Coronary Syndromes"],"prefix":"10.1016","volume":"12","author":[{"given":"Sukhdeep S.","family":"Basra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hfc.2015.08.004_bib1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ahj.2008.07.028","article-title":"Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006","volume":"156","author":"Peterson","year":"2008","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjmed.2010.07.023","article-title":"Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI","volume":"124","author":"McManus","year":"2011","journal-title":"Am J Med"},{"issue":"23","key":"10.1016\/j.hfc.2015.08.004_bib3","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction","volume":"362","author":"Yeh","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hfc.2015.08.004_bib4","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1161\/CIR.0b013e31828478ac","volume":"127","author":"Anderson","year":"2013","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.hfc.2015.08.004_bib5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1553-2712.2006.tb00978.x","article-title":"Application of the TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome to an unselected emergency department chest pain population","volume":"13","author":"Pollack","year":"2006","journal-title":"Acad Emerg Med"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.004_bib7","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the global registry of acute coronary events","volume":"163","author":"Granger","year":"2003","journal-title":"Arch Intern Med"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.004_bib8","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1161\/01.CIR.101.22.2557","article-title":"Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators","volume":"101","author":"Boersma","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib9","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study","volume":"309","author":"Lewis","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"8719","key":"10.1016\/j.hfc.2015.08.004_bib10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group","volume":"336","year":"1990","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.hfc.2015.08.004_bib11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"7329","key":"10.1016\/j.hfc.2015.08.004_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.004_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14728214.8.2.349","article-title":"Advances in antiplatelet therapy","volume":"8","author":"Jneid","year":"2003","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Writing Committee","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.004_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.163.10.1145","article-title":"Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study","volume":"163","author":"Jneid","year":"2003","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.004_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"Holmes","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.004_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0749-3797(18)30950-4","article-title":"Preventive medicine, public health, and the environmental movement","volume":"7","author":"Guidotti","year":"1991","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.004_bib19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.004_bib21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"9694","key":"10.1016\/j.hfc.2015.08.004_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.hfc.2015.08.004_bib23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hfc.2015.08.004_bib24","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.004_bib25","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.hfc.2015.08.004_bib26","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hfc.2015.08.004_bib27","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.hfc.2015.08.004_bib28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.004_bib29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2015.08.004_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.004_bib31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"9302","key":"10.1016\/j.hfc.2015.08.004_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.hfc.2015.08.004_bib33","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators","volume":"340","author":"Hamm","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hfc.2015.08.004_bib34","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/hc4801.100029","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes","volume":"104","author":"Roffi","year":"2001","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.hfc.2015.08.004_bib35","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.004_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/0953710021000024402","article-title":"Comparison of the pharmacodynamic effects of the platelet ADP\u00a0receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease","volume":"13","author":"Storey","year":"2002","journal-title":"Platelets"},{"issue":"24","key":"10.1016\/j.hfc.2015.08.004_bib38","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hfc.2015.08.004_bib39","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.004_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.hfc.2015.08.004_bib41","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.004_bib43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-8703(99)70460-6","article-title":"A\u00a0randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators","volume":"137","author":"Becker","year":"1999","journal-title":"Am Heart J"},{"issue":"9001","key":"10.1016\/j.hfc.2015.08.004_bib45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group","volume":"347","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.004_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib48","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.hfc.2015.08.004_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.0960-135X.2005.01452.x","article-title":"From heparins to factor Xa inhibitors and\u00a0beyond","volume":"35","author":"Alban","year":"2005","journal-title":"Eur J Clin Invest"},{"issue":"14","key":"10.1016\/j.hfc.2015.08.004_bib50","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4 Suppl S","key":"10.1016\/j.hfc.2015.08.004_bib51","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1016\/S0735-1097(02)02687-6","article-title":"The evolving role of direct thrombin inhibitors in acute coronary syndromes","volume":"41","author":"Eikelboom","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.hfc.2015.08.004_bib52","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.004_bib53","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"9497","key":"10.1016\/j.hfc.2015.08.004_bib54","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.004_bib55","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group","volume":"97","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0735-1097(99)00146-1","article-title":"Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group","volume":"34","author":"Gustafsson","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.004_bib57","doi-asserted-by":"crossref","first-page":"1090.e1","DOI":"10.1016\/j.amjmed.2007.02.029","article-title":"Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy","volume":"120","author":"Jneid","year":"2007","journal-title":"Am J Med"},{"issue":"20","key":"10.1016\/j.hfc.2015.08.004_bib58","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hfc.2015.08.004_bib59","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.004_bib60","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","article-title":"Nifedipine. Dose-related increase in mortality in patients with coronary heart disease","volume":"92","author":"Furberg","year":"1995","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib61","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM198608143150704","article-title":"Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial","volume":"315","author":"Gibson","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"2 Pt 2","key":"10.1016\/j.hfc.2015.08.004_bib62","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0002-8703(97)70008-5","article-title":"Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial","volume":"134","author":"Hansen","year":"1997","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.hfc.2015.08.004_bib63","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.hfc.2015.08.004_bib64","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.hfc.2015.08.004_bib65","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1161\/CIRCULATIONAHA.108.191099","volume":"118","author":"Krumholz","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2015.08.004_bib66","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jacc.2006.06.050","article-title":"Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials","volume":"48","author":"Bavry","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9564","key":"10.1016\/j.hfc.2015.08.004_bib67","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(07)60410-3","article-title":"Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study","volume":"369","author":"Hirsch","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.004_bib68","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.hfc.2015.08.004_bib69","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1056\/NEJMoa0807986","article-title":"Early versus delayed invasive intervention in acute coronary syndromes","volume":"360","author":"Mehta","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.004_bib70","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2009.1267","article-title":"Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial","volume":"302","author":"Montalescot","year":"2009","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.hfc.2015.08.004_bib71","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","author":"NICE-SUGAR Study Investigators","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9670","key":"10.1016\/j.hfc.2015.08.004_bib72","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0140-6736(09)60552-3","article-title":"Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials","volume":"373","author":"Hlatky","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.004_bib73","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.108.838169","volume":"120","author":"Szummer","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.004_bib74","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.ijcard.2013.06.013","article-title":"Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome","volume":"168","author":"Huang","year":"2013","journal-title":"Int J Cardiol"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.004_bib75","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2011.08.051","article-title":"Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease","volume":"58","author":"Basra","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.004_bib76","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"9748","key":"10.1016\/j.hfc.2015.08.004_bib77","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.004_bib78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hfc.2015.08.004_bib79","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9683","key":"10.1016\/j.hfc.2015.08.004_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.004_bib81","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"APPRAISE Steering Committee and Investigators","year":"2009","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713615000720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713615000720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T09:01:08Z","timestamp":1567328468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713615000720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1551713615000720"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2015.08.004","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Coronary Syndromes","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}